دورية أكاديمية
The role of response adapted therapy in the era of novel agents.
| العنوان: | The role of response adapted therapy in the era of novel agents. |
|---|---|
| المؤلفون: | Schroers-Martin JG; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA., Advani RH; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA. Electronic address: radvani@stanford.edu. |
| المصدر: | Seminars in hematology [Semin Hematol] 2024 Jun 14. Date of Electronic Publication: 2024 Jun 14. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0404514 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8686 (Electronic) Linking ISSN: 00371963 NLM ISO Abbreviation: Semin Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Philadelphia Pa : W.B. Saunders Original Publication: New York. |
| مستخلص: | The optimal treatment of classic Hodgkin Lymphoma (cHL) requires an individualized approach, with therapy guided by pretreatment clinical risk stratification and interim response assessment with positron emission tomography (PET). The overall goal is to achieve high cure rates while minimizing acute toxicity and late therapy-related effects. Interim PET-adapted strategies (iPET) were initially developed with traditional chemotherapy, reducing intensity after interim complete response and escalating treatment for patients with iPET+ disease. Recently, novel agents including brentuximab vedotin and the checkpoint inhibitor immunotherapies (CPIs) pembrolizumab and nivolumab have been adopted into the front-line treatment of cHL, and PET-adapted approaches may be relevant for these drugs as well. In this review we discuss response-adapted strategies utilizing novel agents, consider challenges including indeterminate radiographic findings with CPIs, and address emerging techniques for response assessment including new PET-based imaging metrics and the role of circulating tumor DNA. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.S.M. reports no potential conflicts of interest. R.H.A. reports research funding from Genentech/Roche, Gilead, Merck, Millennium, Pharmacyclics, Regeneron, BeiGene, and Seagen Inc; and has served as a consultant for Autolus, Genentech/Roche, Gilead, and ADCT. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Brentuximab; Hodgkin lymphoma; Nivolumab; Pembrolizumab; Response adapted |
| تواريخ الأحداث: | Date Created: 20240714 Latest Revision: 20240714 |
| رمز التحديث: | 20240715 |
| DOI: | 10.1053/j.seminhematol.2024.06.002 |
| PMID: | 39004520 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-8686 |
|---|---|
| DOI: | 10.1053/j.seminhematol.2024.06.002 |